Richard Smith, MD
Family Medicine · Carrollton, MONPI 1861448664
Payments from drug & device makers
Across 186 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$620
- AstraZeneca$345
- Lilly USA, LLC$327
- Otsuka America Pharmaceutical, Inc.$211
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$190
- Boehringer Ingelheim$173
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,384100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $620 |
| AstraZeneca | 18 | $345 |
| Lilly USA, LLC | 20 | $327 |
| Otsuka America Pharmaceutical, Inc. | 6 | $211 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $190 |
| Boehringer Ingelheim | 8 | $173 |
| Pfizer | 9 | $138 |
| Astellas Pharma US Inc | 5 | $118 |
| Amgen | 7 | $115 |
| Novo Nordisk | 7 | $103 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| Johnson & Johnson | 6 | $84 |
| Sanofi-aventis U.S. LLC | 3 | $78 |
| Novartis | 4 | $66 |
| Merck | 4 | $66 |
| Lundbeck LLC | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Mylan Specialty L.p. | 2 | $37 |
| Organon | 2 | $36 |
| Abbott | 2 | $33 |
| Circassia Inc. | 2 | $30 |
| Melinta Therapeutics, LLC | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Vertex | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Biogen | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Bayer | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$106
How this compares
$3,384 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 97 | $291,685 |
| EliquisApixaban | 615 | $266,772 |
| OzempicSemaglutide | 139 | $139,060 |
| JardianceEmpagliflozin | 295 | $135,839 |
| RexultiBrexpiprazole | 154 | $128,506 |
| XareltoRivaroxaban | 278 | $126,839 |
| AustedoDeutetrabenazine | 15 | $104,175 |
| JanuviaSitagliptin Phosphate | 250 | $100,877 |
| MyrbetriqMirabegron | 177 | $58,897 |
| EntrestoSacubitril/Valsartan | 116 | $52,964 |
| TrulicityDulaglutide | 44 | $45,397 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 75 | $43,059 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $42,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $40,037 |
| Incruse ElliptaUmeclidinium Bromide | 101 | $39,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $84 | $418,524375 claims |
| PfizerEliquis | $138 | $266,772615 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $173 | $188,242391 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Shingrix, Anoro Ellipta | $12 | $153,302362 claims |
| Novo NordiskOzempic, Rybelsus | $103 | $152,509152 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $211 | $128,506154 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $99 | $104,17515 claims |
| MerckJanuvia | $66 | $100,877250 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $58,897177 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $327 | $57,43357 claims |
| AbbVieVraylar, Linzess | $620 | $56,04273 claims |
| NovartisEntresto | $66 | $52,964116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Carrollton
- Pamela RallsCarrollton$20K
- Andrew HorineCarrollton$19K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.